Kezar Life Sciences has announced the dosing of the first subject in the Phase I KZR-261-101 clinical trial of a new therapy, KZR-261, in advanced solid tumour malignancies.
Discovered by Kezar, the broad-spectrum anti-tumour agent KZR-261 acts through direct interaction and hinders Sec61 activity.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The open-label, multicentre Phase I trial in subjects with solid tumour malignancies will be carried out in two parts, dose-escalation and dose-expansion.
It will assess the tolerability, safety, pharmacokinetics and pharmacodynamics of KZR-261 in patients with locally advanced or metastatic disease.
The trial will also evaluate the initial anti-tumour activity of the treatment.
On concluding safety analysis of all dose-escalation arms and deciding on the maximum tolerated dose or administered dose, the therapy will be assessed for safety and preliminary efficacy.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThis will be carried out in four tumour-specific arms and one all-tumour arm for determining doses recommended for Phase II clinical trials.
Kezar Life Sciences co-founder and CEO John Fowler said: “Dosing the first patient with KZR-261, the first clinical candidate from our novel protein secretion platform, is an exciting milestone for Kezar as we continue to advance our oncology program and mature into a multi-asset therapeutics company.
“We believe KZR-261 has a differentiated therapeutic profile, which could translate into broad potential across the oncology landscape.”
KZR-261 has shown various promising features that lead to its potential to be an anti-cancer agent.
A Phase I trial is currently progressing to treat solid tumour malignancies.
Kezar Life Sciences’ lead development candidate KZR-616 is a selective immunoproteasome inhibitor and is being assessed in Phase II studies for lupus nephritis, dermatomyositis and polymyositis treatments.
